Sanctuary Advisors LLC Invests $605,000 in HealthEquity, Inc. $HQY

Sanctuary Advisors LLC bought a new position in shares of HealthEquity, Inc. (NASDAQ:HQY) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,695 shares of the company’s stock, valued at approximately $605,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Acumen Wealth Advisors LLC purchased a new stake in shares of HealthEquity in the fourth quarter valued at about $27,000. Aster Capital Management DIFC Ltd acquired a new stake in HealthEquity in the 4th quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of HealthEquity by 1,723.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $28,000 after buying an additional 293 shares during the period. Leonteq Securities AG increased its stake in HealthEquity by 159.9% during the first quarter. Leonteq Securities AG now owns 382 shares of the company’s stock worth $32,000 after purchasing an additional 235 shares during the period. Finally, Silvant Capital Management LLC purchased a new stake in HealthEquity during the 2nd quarter worth approximately $35,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity News Roundup

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: HealthEquity exceeded expectations with adjusted earnings of $1.24 per share versus the $1.19 consensus, while revenue reached $350.7 million, slightly above estimates. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and net margin expanding to 19% from 18%. Adjusted EBITDA grew 11% to $167 million, while its margin increased to 48% from 46%. HealthEquity Second-Quarter Financial Results
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion provide additional support for the company’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and raised its price target to $115. Another analysis indicated that HQY could be approximately 19% undervalued after the guidance increase, reinforcing the bullish interpretation of the earnings update. BTIG Research Rating HealthEquity Could Be Undervalued
• Neutral Sentiment: Fiscal 2027 revenue guidance of approximately $1.4 billion was broadly in line with expectations, so the guidance improvement was driven mainly by stronger anticipated earnings and margins.
• Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares valued at approximately $798,000, reducing his position by 10.9%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces its negative signaling value but could still attract investor attention. HealthEquity Director Stock Sale
• Negative Sentiment: HQY trades at a premium valuation of roughly 35 times earnings. After the recent advance toward its 52-week high, some investors may lock in gains, potentially tempering the stock’s reaction to otherwise favorable fundamentals.

Insiders Place Their Bets

In related news, Director Adrian T. Dillon sold 7,632 shares of HealthEquity stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total transaction of $798,383.52. Following the completion of the sale, the director owned 62,395 shares in the company, valued at approximately $6,527,140.95. This trade represents a 10.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,470 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $95.00, for a total transaction of $234,650.00. Following the completion of the transaction, the executive vice president directly owned 56,643 shares of the company’s stock, valued at approximately $5,381,085. This represents a 4.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 12,456 shares of company stock valued at $1,256,664. Insiders own 1.60% of the company’s stock.

HealthEquity Price Performance

Shares of NASDAQ:HQY opened at $96.37 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.99 and a quick ratio of 3.44. The firm has a market capitalization of $8.06 billion, a price-to-earnings ratio of 34.79, a price-to-earnings-growth ratio of 1.62 and a beta of 0.21. HealthEquity, Inc. has a 12 month low of $72.76 and a 12 month high of $107.62. The business’s 50 day simple moving average is $98.16 and its 200-day simple moving average is $87.87.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Thursday, August 27th. The company reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.05. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%.The business had revenue of $350.73 million during the quarter, compared to analysts’ expectations of $349.22 million. The business’s quarterly revenue was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, equities analysts forecast that HealthEquity, Inc. will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HQY. Barrington Research restated an “outperform” rating and set a $110.00 price target on shares of HealthEquity in a report on Friday, May 22nd. KeyCorp reiterated an “overweight” rating on shares of HealthEquity in a research note on Tuesday, May 26th. Wells Fargo & Company set a $111.00 price target on HealthEquity in a research report on Monday, June 1st. Royal Bank Of Canada raised their price target on HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Finally, Citigroup restated a “market outperform” rating on shares of HealthEquity in a research note on Friday. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $110.93.

HealthEquity Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.